Abstract
Abstract Objectives An excessive inflammatory response to SARS-CoV-2 is thought to be a major cause of disease severity in COVID-19. The aim herein was to determine the prognostic value of IL-6, and demonstrate the comparison between IL-6 and related parameters in COVID-19. Methods Data were collected from 115 COVID-19 patients. Results The median age was 46.04 years in the mild group, 56.42 years in the moderate group, and 62.92 years in the severe group (p=0.001). There was a significant difference in the hospitalized clinic to intensive care unit ratio among the patients (p<0.001). The IL-6 values were significantly higher in the severe group than those in the mild (p=0.04) and moderate groups (p=0.043). The area under the receiver operating characteristic curve for IL-6, as predictor of severe clinical condition, was 0.864 (95% CI 0.765–0.963 p=0.000). The longitudinal analyses showed that the severe group presented with significantly increased IL-6 levels during hospitalization. Conclusions IL‐6 seemed to be a guide in the early diagnosis of severe COVID-19 and an ideal marker for monitoring negative outcome.
Highlights
A highly contagious and lethal respiratory disease, which emerged in Wuhan, China, was declared an international pandemic outburst of pneumonia named coronavirus disease 2019 (COVID-19) [1,2,3]
The occurrence of an excessive inflammatory response to SARS-CoV-2 is believed have a significant effect on disease severity and death in patients who are infected with COVID-19, and has been shown to have an association with high circulating cytokines levels, severe lymphopenia, and a substantial degree of mononuclear cell infiltration in the lungs, spleen, heart, kidney, and lymph nodes, as observed through postmortem analyses [6, 8]
There were no significant differences in the male 60 patients included in the study were confirmed to be positive for COVID-19 infection as the result of SARS-CoV-2 nucleic acid real-time polymerase chain reaction (RT-PCR) analysis. 55 patients were cofirmed to be negative for COVID-19 as the result of SARS-CoV-2 RT-PCR
Summary
A highly contagious and lethal respiratory disease, which emerged in Wuhan, China, was declared an international pandemic outburst of pneumonia named coronavirus disease 2019 (COVID-19) [1,2,3]. Approximately 15% of COVID-19 infected patients experience a severe form of the disease that necessitates oxygen support, while about 5% experience a highly critical and life-threatening form of the disease, in addition to complications, which can include acute respiratory distress syndrome, respiratory failure, sepsis and septic shock, and thromboembolism, in addition to multiorgan failure, which includes acute kidney and cardiac injury [2, 4, 5]. The causes behind the development of severe or critical forms of COVID-19 infection in individuals who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have not yet been fully understood, and the progress of the severe form of the disease seems to be related to more than just the viral load, and may possibly be interrelated with a defective interferon response [6, 7]. The occurrence of an excessive inflammatory response to SARS-CoV-2 is believed have a significant effect on disease severity and death in patients who are infected with COVID-19, and has been shown to have an association with high circulating cytokines levels, severe lymphopenia, and a substantial degree of mononuclear cell infiltration in the lungs, spleen, heart, kidney, and lymph nodes, as observed through postmortem analyses [6, 8].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
